Primenenie biguanidov pri sindromepolikistoznykh yaichnikov

1. Курмачева Н.А., Саяпин С.В., Киреев Р.Ф., Крутцова О.В. и др. Опыт применения сиофора (метформина) у женщин с абдоминальным ожирением и бесплодием. // Пробл. репродукции - 2003. - Т. 9. - № 2.- C. 51-54.

2. Мамедов М.Н., Метельская В.В., Перова Н.В. Метаболический синдром: пути реализации атеротромбогенного потенциала. // Кардиология. - 2000. - № 2. - C. 83-89.

3. Шостак Н.А., Аничков Д.А. К вопросу о диагностических критериях метаболического синдрома. // РМЖ. - 2002. - T. 10. - № 27 (171). - C. 1255-1257

4. Acbay O., Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? // Fertil. аnd Steril. - 1996. - v. 65. - p. 946-949.

5. Andersen P. et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. // Metabolism. - 1995.- v. 44.- p. 611-617.

6. Argaud D. Roth H, Wiemsperger N. et al. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. // Eur. J. Biochem. - 1993. - v. 213. - p. 1341-1348.

7. Barbieri R.L., Hornstein M.D. Hyperinsulinemia and ovarian hyperandrogenism: cause and effect. // Endocrinol. Metab. Clin. North. Am. - 1988. -v. I7.- p. 685-697

8. Barbieri R.L., Makris A., Ryan KJ. Insulin stimulates androgen accumulation in incuba- tion of human ovarian stroma and theca. // Obstet. Gynecol. - 1984.- v. 64. - р.73-80.

9. Caro F. Insulin resistance in obese and nonobese man. // Clin. Endocrinol. Metab. - 1991. - v. 73. - p. 691 - 695.

10. Col V. New insights into insulin resistance pathophysiology: how it affects glucose and lipid metabolism. // Rev. Assoc. Belge technol. lab. - 2002. -v. 29. - No 1.- p. 9-19.

11. Diamanti-Kandarakis E., Kouli C., Tsianateli T., Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syn- drome. // European J. of Endocrinol. - 1998. - v. 138. - p. 269-274.

12. Dunaif A., Finegood D.T. _-Cell dysfunction independent of obesity and glucose intolerance in polycystic ovary syndrome. // J. Clin. Endocrinol. Metab. - 1996. - v.81. - p. 942-947.

13. Ehrmann D. A., Cavaghan M. K., Imperial J. et al. Effects of metformin on insulin secretion in polycystic ovary syndrome // J. Clin. Endocrinol. - 1995. - v. 72. - p. 489- 512.

14. Ehrmann D.A., Barnes R.B., Rosenfield R.L. Polycystic ovary syndrome as form functional ovarian hyperandrogenism due to dysregulation of androgen secretion. // Endocrine Reviews. - 1995. - v. 16. - p. 322-353.

15. Fischer-Y., Thomas-J., Rosen-P., Kammermeier-H. Action of Metformin on Glucose- Transport and Glucose-Transporter Glut 1 Glut 4 in Heart-Muscle Cells from Hearlthy and Diabetic Rats. // Endocrinology. - 1995. - v. 136. - Iss 2. - p. 412-420.

16. Gdansky E., Diamant Y.Z., Silbergeld A., Kaplan B., Eshet R. //Clin. Endocrinol. - 1997. - v. 47, № 2. - p. 185-190.

17. Klinger B., Anin S., Sibergeld A., Eshet R., Laron Z. Development of hyperandro- genism during treatment with insulin-like growth factor-1 (IGF-1) in female patients with Laron syndrome. // Clin. Endocrinol.-1998. - v. 48. - №1. - p.81-87.

18. Landin K, Tengborn L, Smith U. Metformin and metoprolol CR treatment in nonobese men. // J. Intern. Med. - 1994 Apr. - v. 235. - p. 335-341.

19. Marterns J.W.M., Geller D.H., Arlt W., Auchus R.J., Ossovskaaya V.S., Rodrigues H., Dunaif F., Miller W.L.. Enzymatic Activities of P450c17 Stably Expressed in Fibroblasts from Patients with the Polycystic Ovary Syndrome. // J. Clin. Endocrinol. and Metab. - 2000 Novembrer - v. 85 - No 11 - p. 4338-4352.